Advances in paclitaxel combinations for treating cervical cancer.
Luigi Della CorteFabio BarraVirginia ForestePierluigi GiampaolinoGiulio EvangelistiSimone FerreroGiuseppe BifulcoPublished in: Expert opinion on pharmacotherapy (2020)
In recent years, it has been demonstrated that cisplatin-based doublets, and in particular, cisplatin plus paclitaxel, are superior to cisplatin as a monotherapy in terms of response rate and progression-free survival of patients with advanced cervical cancer. This double regime combined with bevacizumab is also considered the first-line option for metastatic or recurrent disease. Dose-dense paclitaxel in neo-adjuvant chemotherapy combinations is a promising option in patients with locally advanced cervical cancer. Exploration of novel biological therapies and in vitro combinations based on the use of paclitaxel is warranted.